Lindström, U.; Di Giuseppe, D.; Delcoigne, B.; Glintborg, B.; Möller, B.; Ciurea, A.; Pombo-Suarez, M.; Sanchez-Piedra, C.; Eklund, K.; Relas, H.; Gudbjornsson, B.; Love, T.J.; Jones, G.T.; Codreanu, C.; Ionescu, R.; Nekvindova, L.; Závada, J.; Atas, N.; Yolbas, S.; Fagerli, K.M.; Michelsen, B.; Rotar, Z.; Tomšič, M.; Iannone, F.; Santos, M.J.; Avila-Ribeiro, P.; Ørnbjerg, L.M.; Østergaard, M.; Jacobsson, L.T.H.; Askling, J.; Nissen, M.J.
(2021)
Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although ...